AI Drug Discovery for Pharma and Biotech

Drug discovery

160

papers

On emerging therapies

Overview

Acute Generalized Exanthematous Pustulosis (AGEP) is a rare, severe cutaneous adverse reaction characterized by rapid onset of sterile, nonfollicular pustules on erythematous skin, fever, and neutrophilia. Over 90% of cases are drug-induced, commonly by antibiotics (e.g., penicillins, sulfonamides), antifungals, or hydroxychloroquine. AGEP typically resolves within 1–2 weeks after discontinuing the offending agent. Systemic involvement (e.g., liver, kidney) occurs in up to 20% of cases, but mortality remains low (<5%) [1][2][10][12].

Population

  • Incidence: 1–5 cases per million annually; higher prevalence in women (~60%) and adults (median age 56 years) [2][7][12].

  • Risk factors: Obesity, HLA allele associations (e.g., IL36RN mutations), and recent medication use (latency 1–48 hours for antibiotics) [2][4][12].

Burden

  • Morbidity: Self-limiting but may require hospitalization for systemic complications (e.g., hepatitis, acute kidney injury) in 17–20% of patients [1][7][10].

  • Economic impact: Hospital costs and delayed resolution (e.g., hydroxychloroquine-associated AGEP may persist ≥1 month) [7][10].

  • Mortality: <5%, typically due to comorbidities or superinfections [5][10].

Therapies

  • First-line: Immediate discontinuation of the causative drug and supportive care (hydration, antipyretics) [1][5][10].

  • Topical/systemic steroids: Used for pruritus and inflammation; systemic steroids reserved for severe cases or organ involvement [3][12].

  • Biologics: Secukinumab (IL-17 inhibitor) reported effective in steroid-refractory cases [3][7].

Categories: rare skin diseases

Research Papers

160 drug discovery papers about Acute generalized exanthematous pustulosis, with 1 first-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:

160 drug discovery papers about Acute generalized exanthematous pustulosis, with 1 first-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-06-24 | Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Cutaneous adverse drug reactions (cADRs) are unintended and harmful skin responses to medications that impose significant clinical and economic burdens worldwide. The increasing use of novel agents, particularly immune checkpoint inhibitors, has further compounded this challenge. While most cADRs are mild and resolve upon drug discontinuation, approximately 2-6.7% progress to severe, potentially fatal conditions. The most common severe forms include acute generalized exanthematous pustulosis, Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, and drug-associated bullous pemphigoid. Current therapeutic options for refractory cADRs remain limited, primarily relying on systemic corticosteroids, conventional immunosuppressants, and intravenous immunoglobulin. Growing insights into disease pathogenesis and the subsequent repurposing of novel targeted therapies offer promising solutions to the persistent challenges of cADRs. Emerging agents, such as biologics targeting tumor necrosis factor-α, interleukins (IL-4/IL-13, IL-5, IL-6, IL-17, IL-36), immunoglobulin E, and CD20, along with small molecule inhibitors of Janus kinases and phosphodiesterase 4, hold the potential to revolutionize management paradigms, though their long-term efficacy and safety profiles await robust clinical validation.

Open article ↗



2026-06-01 | A rare case of acute generalized exanthematous pustulosis-like Sweet syndrome.

Acute generalized exanthematous pustulosis (AGEP) is a pustular drug eruption characterized by superficial pustules, commonly caused by β-lactam antibiotics. Management of AGEP involves discontinuation of the offending medication and supportive therapy with topical corticosteroids and analgesia, given the self-limiting nature of this condition. In contrast, Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is characterized by the sudden onset of painful, inflamed skin lesions associated with fever. SS typically requires investigations for associated conditions and systemic corticosteroids, resulting in rapid improvement within days. We present a case of AGEP-like SS, initially diagnosed clinically as AGEP in the setting of intravenous antibiotic use, where the patient deteriorated, despite antibiotics being stopped. Skin biopsy revealed papillary dermal oedema with neutrophilic infiltrate, and scattered histiocytoid cells and eosinophils, resulting in a revised diagnosis of AGEP-like SS. The patient was started on oral corticosteroids and achieved complete resolution of disease within 2 days. This case highlights AGEP-like SS as an important differential diagnosis in patients presenting with AGEP-like eruptions, as the management of AGEP and SS is different.

Open article ↗



2026-04-17 | Apalutamide-induced severe cutaneous adverse reactions in prostate cancer: a comprehensive review of reported cases and clinical strategies.

Prostate cancer (PCa) is the most common fatal malignancy among men and a major cause of cancer-related death. Apalutamide, a second-generation androgen receptor inhibitor, is approved for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). However, an increasing number of potentially life-threatening severe cutaneous adverse reactions (SCARs) associated with apalutamide have raised clinical concerns. This review aims to characterize apalutamide-induced SCARs and summarize effective management strategies based on reported cases. We systematically searched PubMed, Europe PMC, and CNKI for case reports of SCARs associated with apalutamide. Keywords included "Apalutamide" and "Drug eruptions." A total of 18 cases were identified and analyzed. We reviewed the clinical characteristics and treatment of 3 cases of DRESS, 14 cases of SJS/TEN, and 1 case of AGEP, all highly suspected to be caused by apalutamide, reported globally. The most frequent SCARs associated with apalutamide are SJS/TEN. The median onset time of SCARs in these cases was 39.5 days, significantly shorter than the onset time of rash in phase III clinical trials of apalutamide. Geographically, the majority of reported cases originated from East Asia. By analyzing the treatment regimens and clinical outcomes of these patients, combined with a literature review, we proposed a set of definitive therapeutic strategies. Apalutamide-induced SCARs tend to occur earlier than common rashes observed in clinical trials, with a predominance of reported cases in East Asian populations. Immediate discontinuation of the suspected drug is the cornerstone of SCAR management. Supportive care, systemic corticosteroids, intravenous immunoglobulin (IVIG), cyclosporine, plasmapheresis, and TNF-α antagonists play important roles in treatment. Personalized dosing strategies based on body weight or body surface area, along with proactive rash management, may help mitigate risk and optimize therapeutic continuity.

Open article ↗



2026-03-30 | Case Report: Secukinumab induced pustular eruption in a patient with ankylosing spondylitis.

We report a case of a 33-year-old male with ankylosing spondylitis (AS) who had been receiving secukinumab (150 mg monthly) for 2 years. Approximately 1 year after initiating treatment, the patient developed recurrent, multiple sterile pustules on the palms and soles. Various topical treatments, including corticosteroids and calcipotriol, yielded minimal improvement. 1 week prior to presentation, new pustular lesions emerged on the trunk and extremities, accompanied by pruritus followed by burning sensations and tenderness. Histopathological examination revealed subcorneal pustule formation within the epidermis and sparse lymphocytic infiltration in the dermis. A diagnosis of secukinumab-induced pustular reaction was made. Following the discontinuation of secukinumab and the initiation of upadacitinib (15 mg/day) for over 1 month, the pustules largely resolved, and symptoms were significantly alleviated. This case suggests that IL-17A inhibitors may trigger pustular cutaneous reactions in AS patients. Clinicians should remain vigilant regarding such adverse effects and adjust treatment regimens promptly. JAK inhibitors may provide an effective therapeutic option for managing these drug-induced reactions.

Open article ↗



2026-03-03 | Acute Generalized Exanthematous Pustulosis in a Neonate Following Hepatitis B Vaccination: A Case Report.

Acute generalized exanthematous pustulosis (AGEP) is a rare severe cutaneous adverse reaction in neonates and is most commonly drug-induced. Vaccine-associated cases are uncommon in this age group. We report a term male neonate who developed clusters of non-follicular pustules on erythematous plaques approximately 6 hours after receiving a birth dose of hepatitis B vaccine. The infant remained clinically stable, without fever or systemic involvement, and had no exposure to concomitant medications. The rapid onset following a single exposure, characteristic morphology, and prompt resolution were highly suggestive of AGEP. Laboratory investigations and skin biopsy were not performed due to rapid clinical improvement. Infectious etiologies and transient neonatal pustular dermatoses were considered less likely based on the clinical course. Patch testing with the same vaccine lot was positive, supporting a type IV hypersensitivity mechanism. The eruption resolved almost completely within 48 hours with topical hydrocortisone, without complications or recurrence.

Open article ↗



antibodies
2026-09-23 | Acute Generalized Exanthematous Pustulosis As A Cause of Exfoliative Dermatitis: A Case Report

Introduction: Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous adverse drug reaction characterized by an acute sterile pustular eruption and may present as erythroderma with extensive desquamation. Case Presentation: A 59-year-old man presented with generalized erythema, pustules, fever, and extensive desquamation after exposure to multiple medications. Examination revealed diffuse erythematous plaques, scaling, erosions, and confluent pustules. Laboratory evaluation showed leukocytosis and elevated C-reactive protein. Histopathology demonstrated subcorneal pustules with neutrophilic and lymphocytic infiltrates, with negative microbiological investigations. A EuroSCAR score of 10 confirmed definite AGEP. The patient improved markedly within 9 days after withdrawal of suspected drugs, systemic corticosteroids, and supportive treatment, allowing discharge with good skin condition. Discussion: AGEP is an important cause of acute erythroderma and may be triggered by medications such as amoxicillin and analgesics. Recurrence may occur following re-exposure. Conclusion: AGEP should be considered in patients with acute erythroderma and pustules following recent drug exposure.

Open article ↗



2026-08-17 | Severe cutaneous adverse reactions and their association with autoimmune disease: an update

Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), are T-cell-mediated hypersensitivity reactions. Although their causative agents and acute manifestations are well characterized, limited data exist regarding their long-term sequelae, particularly the subsequent development of autoimmune disease. A comprehensive literature review was conducted using PubMed. Given the limited published evidence regarding autoimmune sequelae following SCARs, the search strategy was intentionally broad and included studies published from the 1980s through 2025. Among SCARs, DRESS demonstrated the strongest association with autoimmune disease, including type 1 diabetes mellitus, thyroiditis, bullous pemphigoid, thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, vitiligo, and systemic lupus erythematosus. Proposed pathogenic mechanisms include viral reactivation and persistent immune dysregulation. SJS/TEN has also been associated with fulminant type 1 diabetes mellitus, autoimmune thyroid disease, systemic lupus erythematosus, Sjögren’s syndrome, and the development of positive antinuclear antibodies. In contrast, evidence linking AGEP to autoimmune disease remains limited and conflicting, although associations with CARD14 mutations and polyarteritis nodosa have been reported. Evidence supporting post-SCAR autoimmunity, particularly following DRESS, is growing but remains largely based on case reports and small observational studies. SCARs, particularly DRESS and to a lesser extent SJS/TEN, may predispose patients to autoimmune disease through persistent immune dysregulation and viral reactivation. In contrast, no clear association has been established between AGEP and autoimmune disease. Clinicians should remain vigilant for potential long-term autoimmune sequelae following SCARs and consider multidisciplinary follow-up when clinically appropriate. Further prospective studies are needed to better characterize the underlying mechanisms, incidence, and optimal long-term surveillance strategies associated with these conditions.

Open article ↗



2026-07-20 | Desquamating Skin Diseases Requiring Burn Team Involvement: Spectrum, Clinical Outcomes, and Management, A Scoping Review

This scoping review aims to map the existing literature on non-burn desquamating, exfoliative, blistering, bullous, and epidermal detachment skin diseases requiring burn team involvement. These conditions may include Stevens-Johnson syndrome/toxic epidermal necrolysis, staphylococcal scalded skin syndrome, pemphigus, pemphigoid, linear IgA bullous dermatosis, DRESS, AGEP, severe cutaneous adverse reactions, and other related dermatologic conditions associated with significant skin loss. The purpose of this review is to characterize the spectrum of diseases managed with burn team involvement, describe the inpatient care settings in which these patients are treated, and summarize the role of burn teams in management. Burn team involvement may include primary admission under a burn service, co-management with another specialty, or consultative input for wound care, dressing management, surgical procedures, or other clinical decision-making. This review will also chart reported outcomes and management variables, including diagnosis at referral or admission, confirmed diagnosis, physical care setting, burn team role, wound care approaches, surgical interventions, immunomodulatory therapies, ICU admission, length of stay, mortality, complications, and resource utilization where available. Findings will be synthesized descriptively to identify patterns in the literature, highlight gaps in current evidence, and inform future research on the role of burn teams in the care of patients with severe non-burn desquamating skin disease.

Open article ↗



2026-06-08 | When Conventional Therapy Fails: IL-36 Inhibition for Severe Hydroxychloroquine-Induced Acute Generalized Exanthematous Pustulosis in Systemic Lupus Erythematosus: A Case Report

Introduction: Acute generalized exanthematous pustulosis (AGEP) is a rare but severe cutaneous adverse drug reaction characterized by the sudden onset of widespread sterile pustules on an erythematous and edematous base, often accompanied by fever and neutrophilia. Over 90% of cases are drug-induced. Its management can be particularly challenging in patients with autoimmune diseases such as systemic lupus erythematosus (SLE), where cutaneous manifestations and immune dysregulation may confound clinical assessment. Case Presentation: We report a case of severe hydroxychloroquine-induced AGEP in a patient with active SLE. The disease was refractory to systemic corticosteroids and further worsened after IVIG infusion. Given the emerging role of IL-36 pathway dysregulation in pustular dermatoses, the patient was treated with spesolimab, a monoclonal antibody targeting the IL-36 receptor, resulting in rapid defervescence and near-complete resolution of pustules within days. Conclusion: This case underscores the need for prompt recognition of drug-induced AGEP in patients receiving antimalarials or other immunomodulatory agents for connective tissue diseases. Crosstalk between IL-36 signaling and neutrophil extracellular traps (NETs) may amplify inflammation, linking AGEP with autoimmune pathology. IL-36 inhibition with spesolimab represents a potential rescue therapy for severe, treatment-refractory AGEP, particularly in patients with underlying autoimmune disorders where conventional therapies fail.

Open article ↗



2026-05-01 | C50-29 From Rash to Shock: A Life Threatening Presentation of Acute Generalized Pustular Psoriasis

Abstract Introduction Generalized pustular psoriasis (GPP) is a rare immune-mediated skin disorder representing &lt;1% of psoriasis cases. It is characterized by tender, yellow pustular eruption surrounded by erythema, which can present after chronic psoriasis or acutely with life-threatening complications and high mortality. Diagnosis is challenging because GPP can resemble other pustular dermatoses such as acute generalized exanthematous pustulosis (AGEP). We present a case of acute GPP in multifactorial shock. Case A 37-year-old female with history of celiac disease, Raynaud’s, and migraine, presented to the emergency department with presyncope and worsening rash. One month earlier, she was diagnosed with pustular eruption and treated with steroid injections, cyclosporine, triamcinolone, and hydroxychloroquine without improvement. On arrival, she was noted to have diffuse pustular lesions. She was transferred to a tertiary center for dermatologic evaluation. On arrival, she developed refractory hypotension requiring transfer to the intensive care unit. Dermatology, ENT, and Ophthalmology were consulted given the extensive involvement of her rash. Skin biopsies were obtained. The patient’s shock was treated with fluid resuscitation, empiric antibiotics, and vasopressors. At this time, GPP was the favored diagnosis given the temporal association of the rash with steroid exposure. Addition of steroids for septic shock was avoided. After infection was ruled out after an extensive workup, infliximab was initiated. The rash improved considerably, and she was discharged with a plan to start spesolimab as an outpatient. Discussion Generalized pustular psoriasis is characterized by rapid, generalized, painful erythrodermic eruption with leukocytosis, decreased albumin, and malaise. Diagnosis can be challenging as the rash may resemble AGEP, subcorneal pustular dermatosis, and IgM pemphigus. Differentiating etiology of pustular dermatitis directly impacts management strategy, especially when confounded by refractory shock. For example, early systemic corticosteroids are a mainstay for several diffuse pustular eruptions such as AGEP. Likewise, in typical septic shock, corticosteroids shorten the duration of vasopressor and ventilatory support. In contrast, systemic corticosteroids are generally contraindicated in GPP due to their association with disease exacerbation. In this patient, despite a presumed septic contribution to refractory shock, systemic steroids were intentionally withheld following early recognition of GPP. Biologic therapy, including IL-36, TNF-α, IL-17/17R, and IL-23 inhibitors, is considered first-line once infection is excluded. Infliximab was chosen due to its rapid onset and unavailability of spesolimab. Untreated, GPP may progress to multiorgan failure and death. Early recognition and prompt biologic initiation are essential to reduce morbidity in acute presentations complicated by shock. This abstract is funded by: None

Open article ↗



proteins
2026-06-10 | IL-1-targeted therapy in dermatologic conditions.

Interleukin-1 (IL-1) plays a key role in inflammasome activation, keratinocyte signaling and neutrophil recruitment, and is a driving force behind many neutrophil-rich and suppurative dermatoses. There is robust evidence supporting the use of IL-1 blockade as a disease-modifying therapy in cryopyrin-associated periodic syndromes and other monogenic periodic fever syndromes, as well as in the treatment of Schnitzler syndrome, where it can rapidly control urticarial and neutrophilic eruptions. Cohort- and series-level data demonstrate high efficacy in IL-1 receptor antagonist deficiency and steroid-refractory pyoderma gangrenosum, whereas benefits appear more heterogeneous in hidradenitis suppurativa, pustular psoriasis and proline-serine-threonine phosphatase-interacting protein 1-associated autoinflammatory diseases. In contrast, conditions such as IL-36 receptor antagonist deficiency, synovitis acne pustulosis hyperostosis osteitis syndrome, Sweet syndrome and vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome are supported only by scattered case reports or theoretical rationale, with highly variable or uncertain responses to IL-1 blockade, highlighting the importance of careful clinical and, where possible, genetic phenotyping. We summarize practical considerations for selecting agents, pediatric and adult dosing and safety. IL-1 antagonists are indispensable for a subset of IL-1-driven disorders and represent a rational rescue option for selected neutrophilic dermatoses.

Open article ↗



2023-07-29 | Pustular Eruption following COVID-19 Vaccination: A Narrative Case-Based Review

From the beginning of public vaccinations until the relaxation of COVID-19 measures, many case reports, case series and case–control studies have been published indicating cutaneous side effects of COVID-19 vaccination. Post-vaccination pustular eruption was reported as well, with a challenging differential diagnosis between pustular psoriasis, AGEP (acute generalized exanthematous pustulosis) and neutrophil pustular eruptions. We report a case of 56-year-old woman presented with acute generalized pustular flare up culminated 5 days after the second dose of BNT162b2(Pfizer) vaccination. She was diagnosed with pustular psoriasis flare and due to the regulating role of IL-1 in pustular psoriasis and in the cytokine storm observed in cases of COVID-19 postvaccination inflammation; we decided to treat the patient with an IL-1 antagonist, subcutaneous anakinra (100 mg daily) along with acitretin. One week later, after anakinra withdrawal, she presented a pustular psoriasis flare and a 7-day anakinra re-administration led to a satisfactory improvement in the skin lesions. We also reviewed the medical literature and found 28 case reports with pustular eruption after the COVID-19 vaccination. We compared the patients reported, regarding sex, age, number of doses, post-vaccination period and vaccine brand, and compared those results with our patient. Finally, as indicated by our case and other cases with similarly treated pustular eruptions. targeted therapy to this cytokine imbalance such as anakinra (IL-1) antagonist can improve the clinical course of the patient.

Open article ↗



2022-04-29 | Skin toxicity after Filgrastim treatment for an Ewing's sarcoma patient.

Filgrastim is a granulocyte colony-stimulating factor (GSCF) used in some chemotherapy regimen to prevent febrile neutropenia. Most common reaction of filgrastim are aches and pain including headaches, nausea and skin rash. We report the case of a patient who developed unusual, non-commonly reported adverse toxidermy to filgrastim. At first the eruption was limited to the lower members and genetics organs. Then it slowly spread across the whole body presenting as a polymorphic exanthematous-pustulosis lesions. A cutaneous biopsy was done, identifying a toxidermy modified by systemic treatment. A pharmacological study linked the role of filgrastim to these lesions. After switching from filgrastim to lénograstim, his lesions are completely gone and haven't flared up again. Thus, clearly imputing the use of filgrastim. The cutaneous reaction that has reported with use of GSCF are sweet syndrome, erythema nodosum, pyoderma nodosum and pyoderma gangrenosum. As far as we know, no acute generalized exanthematous pustulosis due to GSCF has been reported.

Open article ↗



small molecules
2026-06-24 | Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Cutaneous adverse drug reactions (cADRs) are unintended and harmful skin responses to medications that impose significant clinical and economic burdens worldwide. The increasing use of novel agents, particularly immune checkpoint inhibitors, has further compounded this challenge. While most cADRs are mild and resolve upon drug discontinuation, approximately 2-6.7% progress to severe, potentially fatal conditions. The most common severe forms include acute generalized exanthematous pustulosis, Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, and drug-associated bullous pemphigoid. Current therapeutic options for refractory cADRs remain limited, primarily relying on systemic corticosteroids, conventional immunosuppressants, and intravenous immunoglobulin. Growing insights into disease pathogenesis and the subsequent repurposing of novel targeted therapies offer promising solutions to the persistent challenges of cADRs. Emerging agents, such as biologics targeting tumor necrosis factor-α, interleukins (IL-4/IL-13, IL-5, IL-6, IL-17, IL-36), immunoglobulin E, and CD20, along with small molecule inhibitors of Janus kinases and phosphodiesterase 4, hold the potential to revolutionize management paradigms, though their long-term efficacy and safety profiles await robust clinical validation.

Open article ↗



2026-06-01 | A rare case of acute generalized exanthematous pustulosis-like Sweet syndrome.

Acute generalized exanthematous pustulosis (AGEP) is a pustular drug eruption characterized by superficial pustules, commonly caused by β-lactam antibiotics. Management of AGEP involves discontinuation of the offending medication and supportive therapy with topical corticosteroids and analgesia, given the self-limiting nature of this condition. In contrast, Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is characterized by the sudden onset of painful, inflamed skin lesions associated with fever. SS typically requires investigations for associated conditions and systemic corticosteroids, resulting in rapid improvement within days. We present a case of AGEP-like SS, initially diagnosed clinically as AGEP in the setting of intravenous antibiotic use, where the patient deteriorated, despite antibiotics being stopped. Skin biopsy revealed papillary dermal oedema with neutrophilic infiltrate, and scattered histiocytoid cells and eosinophils, resulting in a revised diagnosis of AGEP-like SS. The patient was started on oral corticosteroids and achieved complete resolution of disease within 2 days. This case highlights AGEP-like SS as an important differential diagnosis in patients presenting with AGEP-like eruptions, as the management of AGEP and SS is different.

Open article ↗



2026-04-17 | Apalutamide-induced severe cutaneous adverse reactions in prostate cancer: a comprehensive review of reported cases and clinical strategies.

Prostate cancer (PCa) is the most common fatal malignancy among men and a major cause of cancer-related death. Apalutamide, a second-generation androgen receptor inhibitor, is approved for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). However, an increasing number of potentially life-threatening severe cutaneous adverse reactions (SCARs) associated with apalutamide have raised clinical concerns. This review aims to characterize apalutamide-induced SCARs and summarize effective management strategies based on reported cases. We systematically searched PubMed, Europe PMC, and CNKI for case reports of SCARs associated with apalutamide. Keywords included "Apalutamide" and "Drug eruptions." A total of 18 cases were identified and analyzed. We reviewed the clinical characteristics and treatment of 3 cases of DRESS, 14 cases of SJS/TEN, and 1 case of AGEP, all highly suspected to be caused by apalutamide, reported globally. The most frequent SCARs associated with apalutamide are SJS/TEN. The median onset time of SCARs in these cases was 39.5 days, significantly shorter than the onset time of rash in phase III clinical trials of apalutamide. Geographically, the majority of reported cases originated from East Asia. By analyzing the treatment regimens and clinical outcomes of these patients, combined with a literature review, we proposed a set of definitive therapeutic strategies. Apalutamide-induced SCARs tend to occur earlier than common rashes observed in clinical trials, with a predominance of reported cases in East Asian populations. Immediate discontinuation of the suspected drug is the cornerstone of SCAR management. Supportive care, systemic corticosteroids, intravenous immunoglobulin (IVIG), cyclosporine, plasmapheresis, and TNF-α antagonists play important roles in treatment. Personalized dosing strategies based on body weight or body surface area, along with proactive rash management, may help mitigate risk and optimize therapeutic continuity.

Open article ↗



2026-03-30 | Case Report: Secukinumab induced pustular eruption in a patient with ankylosing spondylitis.

We report a case of a 33-year-old male with ankylosing spondylitis (AS) who had been receiving secukinumab (150 mg monthly) for 2 years. Approximately 1 year after initiating treatment, the patient developed recurrent, multiple sterile pustules on the palms and soles. Various topical treatments, including corticosteroids and calcipotriol, yielded minimal improvement. 1 week prior to presentation, new pustular lesions emerged on the trunk and extremities, accompanied by pruritus followed by burning sensations and tenderness. Histopathological examination revealed subcorneal pustule formation within the epidermis and sparse lymphocytic infiltration in the dermis. A diagnosis of secukinumab-induced pustular reaction was made. Following the discontinuation of secukinumab and the initiation of upadacitinib (15 mg/day) for over 1 month, the pustules largely resolved, and symptoms were significantly alleviated. This case suggests that IL-17A inhibitors may trigger pustular cutaneous reactions in AS patients. Clinicians should remain vigilant regarding such adverse effects and adjust treatment regimens promptly. JAK inhibitors may provide an effective therapeutic option for managing these drug-induced reactions.

Open article ↗



2026-03-03 | Acute Generalized Exanthematous Pustulosis in a Neonate Following Hepatitis B Vaccination: A Case Report.

Acute generalized exanthematous pustulosis (AGEP) is a rare severe cutaneous adverse reaction in neonates and is most commonly drug-induced. Vaccine-associated cases are uncommon in this age group. We report a term male neonate who developed clusters of non-follicular pustules on erythematous plaques approximately 6 hours after receiving a birth dose of hepatitis B vaccine. The infant remained clinically stable, without fever or systemic involvement, and had no exposure to concomitant medications. The rapid onset following a single exposure, characteristic morphology, and prompt resolution were highly suggestive of AGEP. Laboratory investigations and skin biopsy were not performed due to rapid clinical improvement. Infectious etiologies and transient neonatal pustular dermatoses were considered less likely based on the clinical course. Patch testing with the same vaccine lot was positive, supporting a type IV hypersensitivity mechanism. The eruption resolved almost completely within 48 hours with topical hydrocortisone, without complications or recurrence.

Open article ↗



antibodies
2026-09-23 | Acute Generalized Exanthematous Pustulosis As A Cause of Exfoliative Dermatitis: A Case Report

Introduction: Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous adverse drug reaction characterized by an acute sterile pustular eruption and may present as erythroderma with extensive desquamation. Case Presentation: A 59-year-old man presented with generalized erythema, pustules, fever, and extensive desquamation after exposure to multiple medications. Examination revealed diffuse erythematous plaques, scaling, erosions, and confluent pustules. Laboratory evaluation showed leukocytosis and elevated C-reactive protein. Histopathology demonstrated subcorneal pustules with neutrophilic and lymphocytic infiltrates, with negative microbiological investigations. A EuroSCAR score of 10 confirmed definite AGEP. The patient improved markedly within 9 days after withdrawal of suspected drugs, systemic corticosteroids, and supportive treatment, allowing discharge with good skin condition. Discussion: AGEP is an important cause of acute erythroderma and may be triggered by medications such as amoxicillin and analgesics. Recurrence may occur following re-exposure. Conclusion: AGEP should be considered in patients with acute erythroderma and pustules following recent drug exposure.

Open article ↗



2026-08-17 | Severe cutaneous adverse reactions and their association with autoimmune disease: an update

Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), are T-cell-mediated hypersensitivity reactions. Although their causative agents and acute manifestations are well characterized, limited data exist regarding their long-term sequelae, particularly the subsequent development of autoimmune disease. A comprehensive literature review was conducted using PubMed. Given the limited published evidence regarding autoimmune sequelae following SCARs, the search strategy was intentionally broad and included studies published from the 1980s through 2025. Among SCARs, DRESS demonstrated the strongest association with autoimmune disease, including type 1 diabetes mellitus, thyroiditis, bullous pemphigoid, thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, vitiligo, and systemic lupus erythematosus. Proposed pathogenic mechanisms include viral reactivation and persistent immune dysregulation. SJS/TEN has also been associated with fulminant type 1 diabetes mellitus, autoimmune thyroid disease, systemic lupus erythematosus, Sjögren’s syndrome, and the development of positive antinuclear antibodies. In contrast, evidence linking AGEP to autoimmune disease remains limited and conflicting, although associations with CARD14 mutations and polyarteritis nodosa have been reported. Evidence supporting post-SCAR autoimmunity, particularly following DRESS, is growing but remains largely based on case reports and small observational studies. SCARs, particularly DRESS and to a lesser extent SJS/TEN, may predispose patients to autoimmune disease through persistent immune dysregulation and viral reactivation. In contrast, no clear association has been established between AGEP and autoimmune disease. Clinicians should remain vigilant for potential long-term autoimmune sequelae following SCARs and consider multidisciplinary follow-up when clinically appropriate. Further prospective studies are needed to better characterize the underlying mechanisms, incidence, and optimal long-term surveillance strategies associated with these conditions.

Open article ↗



2026-07-20 | Desquamating Skin Diseases Requiring Burn Team Involvement: Spectrum, Clinical Outcomes, and Management, A Scoping Review

This scoping review aims to map the existing literature on non-burn desquamating, exfoliative, blistering, bullous, and epidermal detachment skin diseases requiring burn team involvement. These conditions may include Stevens-Johnson syndrome/toxic epidermal necrolysis, staphylococcal scalded skin syndrome, pemphigus, pemphigoid, linear IgA bullous dermatosis, DRESS, AGEP, severe cutaneous adverse reactions, and other related dermatologic conditions associated with significant skin loss. The purpose of this review is to characterize the spectrum of diseases managed with burn team involvement, describe the inpatient care settings in which these patients are treated, and summarize the role of burn teams in management. Burn team involvement may include primary admission under a burn service, co-management with another specialty, or consultative input for wound care, dressing management, surgical procedures, or other clinical decision-making. This review will also chart reported outcomes and management variables, including diagnosis at referral or admission, confirmed diagnosis, physical care setting, burn team role, wound care approaches, surgical interventions, immunomodulatory therapies, ICU admission, length of stay, mortality, complications, and resource utilization where available. Findings will be synthesized descriptively to identify patterns in the literature, highlight gaps in current evidence, and inform future research on the role of burn teams in the care of patients with severe non-burn desquamating skin disease.

Open article ↗



2026-06-08 | When Conventional Therapy Fails: IL-36 Inhibition for Severe Hydroxychloroquine-Induced Acute Generalized Exanthematous Pustulosis in Systemic Lupus Erythematosus: A Case Report

Introduction: Acute generalized exanthematous pustulosis (AGEP) is a rare but severe cutaneous adverse drug reaction characterized by the sudden onset of widespread sterile pustules on an erythematous and edematous base, often accompanied by fever and neutrophilia. Over 90% of cases are drug-induced. Its management can be particularly challenging in patients with autoimmune diseases such as systemic lupus erythematosus (SLE), where cutaneous manifestations and immune dysregulation may confound clinical assessment. Case Presentation: We report a case of severe hydroxychloroquine-induced AGEP in a patient with active SLE. The disease was refractory to systemic corticosteroids and further worsened after IVIG infusion. Given the emerging role of IL-36 pathway dysregulation in pustular dermatoses, the patient was treated with spesolimab, a monoclonal antibody targeting the IL-36 receptor, resulting in rapid defervescence and near-complete resolution of pustules within days. Conclusion: This case underscores the need for prompt recognition of drug-induced AGEP in patients receiving antimalarials or other immunomodulatory agents for connective tissue diseases. Crosstalk between IL-36 signaling and neutrophil extracellular traps (NETs) may amplify inflammation, linking AGEP with autoimmune pathology. IL-36 inhibition with spesolimab represents a potential rescue therapy for severe, treatment-refractory AGEP, particularly in patients with underlying autoimmune disorders where conventional therapies fail.

Open article ↗



2026-05-01 | C50-29 From Rash to Shock: A Life Threatening Presentation of Acute Generalized Pustular Psoriasis

Abstract Introduction Generalized pustular psoriasis (GPP) is a rare immune-mediated skin disorder representing &lt;1% of psoriasis cases. It is characterized by tender, yellow pustular eruption surrounded by erythema, which can present after chronic psoriasis or acutely with life-threatening complications and high mortality. Diagnosis is challenging because GPP can resemble other pustular dermatoses such as acute generalized exanthematous pustulosis (AGEP). We present a case of acute GPP in multifactorial shock. Case A 37-year-old female with history of celiac disease, Raynaud’s, and migraine, presented to the emergency department with presyncope and worsening rash. One month earlier, she was diagnosed with pustular eruption and treated with steroid injections, cyclosporine, triamcinolone, and hydroxychloroquine without improvement. On arrival, she was noted to have diffuse pustular lesions. She was transferred to a tertiary center for dermatologic evaluation. On arrival, she developed refractory hypotension requiring transfer to the intensive care unit. Dermatology, ENT, and Ophthalmology were consulted given the extensive involvement of her rash. Skin biopsies were obtained. The patient’s shock was treated with fluid resuscitation, empiric antibiotics, and vasopressors. At this time, GPP was the favored diagnosis given the temporal association of the rash with steroid exposure. Addition of steroids for septic shock was avoided. After infection was ruled out after an extensive workup, infliximab was initiated. The rash improved considerably, and she was discharged with a plan to start spesolimab as an outpatient. Discussion Generalized pustular psoriasis is characterized by rapid, generalized, painful erythrodermic eruption with leukocytosis, decreased albumin, and malaise. Diagnosis can be challenging as the rash may resemble AGEP, subcorneal pustular dermatosis, and IgM pemphigus. Differentiating etiology of pustular dermatitis directly impacts management strategy, especially when confounded by refractory shock. For example, early systemic corticosteroids are a mainstay for several diffuse pustular eruptions such as AGEP. Likewise, in typical septic shock, corticosteroids shorten the duration of vasopressor and ventilatory support. In contrast, systemic corticosteroids are generally contraindicated in GPP due to their association with disease exacerbation. In this patient, despite a presumed septic contribution to refractory shock, systemic steroids were intentionally withheld following early recognition of GPP. Biologic therapy, including IL-36, TNF-α, IL-17/17R, and IL-23 inhibitors, is considered first-line once infection is excluded. Infliximab was chosen due to its rapid onset and unavailability of spesolimab. Untreated, GPP may progress to multiorgan failure and death. Early recognition and prompt biologic initiation are essential to reduce morbidity in acute presentations complicated by shock. This abstract is funded by: None

Open article ↗



proteins
2026-06-10 | IL-1-targeted therapy in dermatologic conditions.

Interleukin-1 (IL-1) plays a key role in inflammasome activation, keratinocyte signaling and neutrophil recruitment, and is a driving force behind many neutrophil-rich and suppurative dermatoses. There is robust evidence supporting the use of IL-1 blockade as a disease-modifying therapy in cryopyrin-associated periodic syndromes and other monogenic periodic fever syndromes, as well as in the treatment of Schnitzler syndrome, where it can rapidly control urticarial and neutrophilic eruptions. Cohort- and series-level data demonstrate high efficacy in IL-1 receptor antagonist deficiency and steroid-refractory pyoderma gangrenosum, whereas benefits appear more heterogeneous in hidradenitis suppurativa, pustular psoriasis and proline-serine-threonine phosphatase-interacting protein 1-associated autoinflammatory diseases. In contrast, conditions such as IL-36 receptor antagonist deficiency, synovitis acne pustulosis hyperostosis osteitis syndrome, Sweet syndrome and vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome are supported only by scattered case reports or theoretical rationale, with highly variable or uncertain responses to IL-1 blockade, highlighting the importance of careful clinical and, where possible, genetic phenotyping. We summarize practical considerations for selecting agents, pediatric and adult dosing and safety. IL-1 antagonists are indispensable for a subset of IL-1-driven disorders and represent a rational rescue option for selected neutrophilic dermatoses.

Open article ↗



2023-07-29 | Pustular Eruption following COVID-19 Vaccination: A Narrative Case-Based Review

From the beginning of public vaccinations until the relaxation of COVID-19 measures, many case reports, case series and case–control studies have been published indicating cutaneous side effects of COVID-19 vaccination. Post-vaccination pustular eruption was reported as well, with a challenging differential diagnosis between pustular psoriasis, AGEP (acute generalized exanthematous pustulosis) and neutrophil pustular eruptions. We report a case of 56-year-old woman presented with acute generalized pustular flare up culminated 5 days after the second dose of BNT162b2(Pfizer) vaccination. She was diagnosed with pustular psoriasis flare and due to the regulating role of IL-1 in pustular psoriasis and in the cytokine storm observed in cases of COVID-19 postvaccination inflammation; we decided to treat the patient with an IL-1 antagonist, subcutaneous anakinra (100 mg daily) along with acitretin. One week later, after anakinra withdrawal, she presented a pustular psoriasis flare and a 7-day anakinra re-administration led to a satisfactory improvement in the skin lesions. We also reviewed the medical literature and found 28 case reports with pustular eruption after the COVID-19 vaccination. We compared the patients reported, regarding sex, age, number of doses, post-vaccination period and vaccine brand, and compared those results with our patient. Finally, as indicated by our case and other cases with similarly treated pustular eruptions. targeted therapy to this cytokine imbalance such as anakinra (IL-1) antagonist can improve the clinical course of the patient.

Open article ↗



2022-04-29 | Skin toxicity after Filgrastim treatment for an Ewing's sarcoma patient.

Filgrastim is a granulocyte colony-stimulating factor (GSCF) used in some chemotherapy regimen to prevent febrile neutropenia. Most common reaction of filgrastim are aches and pain including headaches, nausea and skin rash. We report the case of a patient who developed unusual, non-commonly reported adverse toxidermy to filgrastim. At first the eruption was limited to the lower members and genetics organs. Then it slowly spread across the whole body presenting as a polymorphic exanthematous-pustulosis lesions. A cutaneous biopsy was done, identifying a toxidermy modified by systemic treatment. A pharmacological study linked the role of filgrastim to these lesions. After switching from filgrastim to lénograstim, his lesions are completely gone and haven't flared up again. Thus, clearly imputing the use of filgrastim. The cutaneous reaction that has reported with use of GSCF are sweet syndrome, erythema nodosum, pyoderma nodosum and pyoderma gangrenosum. As far as we know, no acute generalized exanthematous pustulosis due to GSCF has been reported.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.